Gene Expression, Immunological Status and Metabolome in Glioma Patients
NCT ID: NCT01525459
Last Updated: 2012-02-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
16 participants
OBSERVATIONAL
2010-12-31
2012-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
\* The healthy reference data have been published in collaborative efforts of BTC, UMC and NIB (Gruden et al. 2012).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
An Integrated Radio-immunological Approach
NCT05267509
Determination of Immune Phenotype in Glioblastoma Patients
NCT02751138
Immunophenotyping From Blood of Patients With Malignant Gliomas
NCT02022384
Study of Tissue Samples From Patients With Glioma or Other Brain Tumors
NCT00967200
Validation Study of a Serum-miRNA Signature in Glioma Patients.
NCT06178692
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Glioma patients
Glioma resection
Patients will be treated with the standard surgical therapy - glioma resection.
Blood sampling
Blood samples used for measuring studied parameters will be taken within 10 days before surgery, one day after surgery and once more within 10 days following the operative procedure.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Glioma resection
Patients will be treated with the standard surgical therapy - glioma resection.
Blood sampling
Blood samples used for measuring studied parameters will be taken within 10 days before surgery, one day after surgery and once more within 10 days following the operative procedure.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* metastases
20 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Blood Transfusion Centre of Slovenia
OTHER_GOV
University Medical Centre Ljubljana
OTHER
National Institute of Biology, Slovenia
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Tamara Lah Turnsek
Director of the National Institute of Biology, Slovenia
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Tamara Lah Turnšek, PhD
Role: STUDY_CHAIR
National Institute of Biology, Ljubljana, Slovenia
Kristina Gruden, PhD
Role: PRINCIPAL_INVESTIGATOR
National Institute of Biology, Ljubljana, Slovenia
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Blood Transfusion Centre of Slovenia
Ljubljana, , Slovenia
Department of Neurosurgery, University Medical Centre Ljubljana
Ljubljana, , Slovenia
National Institute of Biology
Ljubljana, , Slovenia
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Marjan Koršič, MD, PhD
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Gruden K, Hren M, Herman A, Blejec A, Albrecht T, Selbig J, Bauer C, Schuchardt J, Or-Guil M, Zupancic K, Svajger U, Stabuc B, Ihan A, Kopitar AN, Ravnikar M, Knezevic M, Rozman P, Jeras M. A "crossomics" study analysing variability of different components in peripheral blood of healthy caucasoid individuals. PLoS One. 2012;7(1):e28761. doi: 10.1371/journal.pone.0028761. Epub 2012 Jan 12.
Related Links
Access external resources that provide additional context or updates about the study.
Official internet page of the Slovenian National Institute of Biology
Official internet page of the project SYSTHER (Systems Biology Tools Development For Cell Therapy And Drug Development)
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MNC-Glioma-1-4
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.